GlassScriptPhysician profile
Cara A Henderson
NPI 1306178827
$1,257.68
in general payments reported to CMS, 2019-2025
30 companies · $684 in 2025
The $684 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $145 · 2024: $428 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,257.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $115.14 | 2024-2025 | |
| Pfizer INC. | $107.71 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $78.92 | 2024-2025 | Spravato, Invega Sustenna |
| Novo Nordisk INC | $73.17 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $64.93 | 2025 | Jardiance |
| Abbott Laboratories | $63.77 | 2024-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $62.64 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $62.00 | 2024-2025 | Airsupra |
| Actelion Pharmaceuticals US, INC. | $61.01 | 2024-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.93 | 2024-2025 | |
| Inspire Medical Systems, INC. | $50.54 | 2025 | Inspire |
| Grifols USA, LLC | $45.55 | 2023-2024 | Prolastin-C Liquid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.47 | 2024 | Xifaxan |
| Biocryst US Sales Co., LLC | $35.36 | 2023 | Orladeyo |
| Astellas Pharma US INC | $33.50 | 2025 | Veozah |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $29.10 | 2023 | Opzelura |
| Amgen INC. | $26.51 | 2024 | Evenity |
| Recordati_rare_diseases_inc. | $24.53 | 2025 | Panhematin |
| Organon LLC | $24.01 | 2024 | |
| Boston Scientific Corporation | $23.36 | 2024 | Watchman Access System |
| Vanda Pharmaceuticals INC. | $22.83 | 2024 | Fanapt, Hetlioz |
| Aimmune Therapeutics, INC. | $22.02 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $20.45 | 2025 | Voquezna |
| Kaleo, INC. | $20.27 | 2023 | Auvi-Q |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.20 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $17.04 | 2025 | Trelegy Ellipta |
| Genentech USA, INC. | $16.48 | 2023 | Xolair |
| Exact Sciences Corporation | $16.26 | 2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $14.07 | 2025 | Korlym |
| Radius Health, INC. | $13.91 | 2025 | Tymlos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.